0

Back to Clinical Utility and Laboratory Testing of New Antimicrobials
Clinical Utility and Laboratory Testing of New Antimicrobials

Clinical Utility and Laboratory Testing of New Antimicrobials

Release Date: Jul 2017

MOC: PC, MK, SBP

Christopher Doern, PhD
Associate Director of Clinical Microbiology, VCU Health System; Assistant Professor of Pathology, VCU School of Medicine, Richmond, VA

 

Description:

This course will discuss the clinical utility and laboratory testing of several newly introduced antimicrobials including isavuconazole, ceftazidime/avibactam, ceftolozane/tazobactam, as well as dalbavancin/oritivancin.  The session will describe the clinical situations in which these drugs will be useful and will review the pertinent literature relevant to their activity against the pertinent organisms.  Lastly, a detailed discussion of the laboratory considerations for providing antimicrobial susceptibility testing for each one of these drugs will be provided. 


After attending this session, participants will be able to:

·       Identify new antibacterial agents and their utility for the treatment of multi-drug resistant infections.

·       Identify new antifungal agents and their utility for the treatment of invasive fungal infections.

·       Describe the laboratory testing considerations for new antimicrobials discussed.


Who should attend?  Practicing Pathologists, Residents, Bench Supervisors, Bench Technologists & Technicians

  • List Price: $275.00 USD

Item Details:
Clinical Utility and Laboratory Testing of New Antimicrobials
Back to Clinical Utility and Laboratory Testing of New Antimicrobials

Bought This Bought That ...